Medical network - March 20, according to flush the data statistics, as of March 16, the existing 30 drug firms announced the total r&d spending in 2016. 

 

Of the 30 companies, total r&d spending is the highest hengrui pharmaceutical, up to 1.1842 billion yuan; Second, the research and development expenses exceeds 200 million yuan (the business that does not contain more than 1 billion yuan) drug firms have four huarun san-jiu, changchun high and new, east China pharmaceutical, global pharmaceutical industry; Research and development expenses exceeds 100 million yuan (the business that does not contain more than 200 million yuan) drug firms have five, Harbin pharmaceutical co, China resources double crane, the company, xinhua figure biological pharmaceutical, Ann. 

 

From the point of research and development costs accounted for the proportion of revenue, flying creatures (10.96%), and Wan Fu biological (11.28%), hengrui medicine (10.68%), Ann figure (10.6%), and other four drug firms r&d costs accounted for the proportion of revenue at more than 10%.